Skip to main
BBIO

BBIO Stock Forecast & Price Target

BBIO Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 62%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Pharma is positioned for positive growth and profitability in the future, with strong results for Attruby and multiple future drug launches. While there are potential risks such as competition and clinical trial setbacks, the company has secured funding and is focused on developing treatments for rare genetic diseases with potential for expanding treatment into other conditions, making it an attractive investment opportunity.

Bears say

BridgeBio Pharma is currently facing significant regulatory and competitive risks, with multiple programs in active regulatory review and potential competition from existing products and product candidates in development. Additionally, the company has incurred a significant amount of debt, which could affect its ability to pursue its strategies and lead to negative impacts on its performance if its core programs are not successful. There are also inherent risks in the biotechnology sector, including clinical and commercial risks, as well as the constant need for significant amounts of capital to fund development.

BBIO has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 62% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Pharma Inc (BBIO) Forecast

Analysts have given BBIO a Buy based on their latest research and market trends.

According to 21 analysts, BBIO has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Pharma Inc (BBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.